PhRMA
@PhRMA
We represent America's innovative biopharmaceutical research & biotechnology companies. @SteveUbl CEO
Our new ad campaign highlights why American patients pay more for prescription medicines than anywhere else: the U.S. lets PBMs, large hospitals and insurers drive up prices for patients while other countries don’t pay their fair share. It’s time to rein in middlemen and end…
A @USCSchaeffer white paper reveals that the IRA doesn’t guarantee lower costs at the pharmacy. Why? Because it does nothing to rein in insurers and PBMs who ultimately control what patients pay out-of-pocket. phrma.org/blog/medicare-…
Another major U.S. investment from @AstraZeneca! PhRMA members continue to support patients, workers and communities across America.
#News for #investors and #media We’re investing $50 billion in medicines manufacturing and R&D in the US by 2030, including the largest single manufacturing investment we’ve ever made—a new state-of-the-art drug substance manufacturing centre in Virginia. #AZN
Yesterday, we recognized our 2024 #WorkingForCures champions and celebrated their accomplishments. Congratulations and thank you again for your tireless dedication to our industry. workingforcures.org
The IP system not only supports the discovery of life-saving medicines, it helps lower long-term costs and protects patient access to treatments. More on the importance of safeguarding the IP ecosystem in General Counsel Jim Stansel’s @NOTUSreports Q&A: notus.org/sponsored/behi…
In the U.S., Pharmacy Benefit Managers (PBMs) charge fees and rebates on medicines that can exceed the total price of that same medicine overseas by as much as 900%. It’s time to rein in the middlemen and lower costs for patients. phrma.org/policy-issues/…
Over the last five years, the U.S. biopharmaceutical industry has invested $85B in research and manufacturing infrastructure, supporting 1,000+ projects and creating good-paying American jobs. @_PILMA’s latest report shows how our industry positively impacts the U.S. economy.…
mRNA technology is more than just a scientific advancement – it’s a transformative tool with precision and versatility to help prevent and treat diseases faster. PhRMA Chief Medical Officer, @mybarra, answers some common questions about mRNA: phrma.org/blog/answering…
We’re proud to welcome @SumitomoPharma as the newest member of PhRMA! They join PhRMA as our fourth new member in the last two years, strengthening our collective voice as we work to defend medical innovation and ensure patients can access and afford the treatments they need.
New insights from Berkeley Research Group reveal the multi-billion-dollar burden of the 340B program on taxpayers. As tax-exempt hospitals continue to take advantage of the 340B program and drain Medicaid resources, the burden on both the government and taxpayers grows as well.…
The #340B program was started to help low-income patients access medicine. But today, it's one of the reasons Americans pay more for medicines than other countries, with big, tax-exempt hospitals marking up medicines by as much as 700% compared to international prices.…
Foreign governments pay less than they should for innovative medicines, relying on U.S. investment to drive progress. This foreign free riding shifts costs to American patients. But the solution isn’t copying foreign price setting policies—it’s ensuring they pay their fair…
